PAT LM1

Drug Profile

PAT LM1

Alternative Names: PAT-LM1

Latest Information Update: 23 Apr 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Patrys
  • Class Antibodies; Antineoplastics
  • Mechanism of Action NONO protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Haematological malignancies; Solid tumours

Most Recent Events

  • 23 Apr 2014 PAT LM1 is available for licensing as of 23 Apr 2014. http://www.patrys.com/
  • 24 Mar 2014 Pharmacodynamics data from a preclinical studies in Haematological maligancies released by Patrys
  • 24 Mar 2014 Preclinical trials in Haematological malignancies prior to March 2014 in Australia (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top